As many as 5% of human cancers appear to be of hereditable etiology. Of the more than 50 characterized familial cancer syndromes, most involve disease affecting multiple organs and many can be traced to one or more abnormalities in specific genes. Studying these syndromes in humans is a difficult task, especially when it comes to genes that may manifest themselves early in gestation. It has been made somewhat easier with the development of genetically engineered mice (GEM) that phenotypically mimic many of these inheritable human cancers. The past 15 years has seen the establishment of mouse lines heterozygous or homozygous null for genes known or suspected of being involved in human cancer syndromes, including APC, ATM, BLM, BRCA1, BRCA2, LKB1, MEN1, MLH, MSH, NF1, TP53, PTEN, RB1, TSC1, TSC2, VHL, and XPA. These lines not only provide models for clinical disease and pathology, but also provide avenues to investigate molecular pathology, gene-gene and protein-tissue interaction, and, ultimately, therapeutic intervention. Possibly of even greater importance, they provide a means of looking at placental and fetal tissues, where genetic abnormalities are often first detected and where they may be most easily corrected. We will review these mouse models, examine their usefulness in medical research, and furnish sources of animals and references.
INTRODUCTION
Chemicals, infectious agents, radiation, diet, lifestyle, and genetics are some of the factors contributing to development of cancer in humans as well as in other animals. The specific causes of the vast majority of cancers are not known, even though exposures to certain agents-such as cigarette smoke, known chemical carcinogens, and viruses-have been repeatedly shown to be causally associated. Genetic predisposition to various cancers has been well known in animals for many years (notably in the mouse), but it has only been with better diagnostic, genetic, molecular, epidemiologic, and data management tools that the concept of human hereditary cancer has become an accepted fact.
There are currently more than 50 human familial cancer syndromes (HFCS) described (4, 74, 94, 102, 103) . In most, the disease has been traced to an aberration in a specific gene or genes, most of which are tumor suppressor genes (TSG) that act as gatekeepers or caretakers for the innumerable proto-oncogenes necessary for normal development and life processes, or in genes coding for genomic repair mechanisms (94) . Genetic abnormalities in transcription factors, either as a primary cause or as a moderating agent, also account for a significant number of hereditary neoplasias. Mutations in proto-oncogenes are actually relatively rare initial events; often they occur secondary to loss of TSG control. Clear Mendelian inheritance is not often seen in HFCS; while many familial cancers appear to be autosomal dominant, many more seem to reflect considerable modification by endogenous and/or exogenous factors. Further, not all are fully penetrant and may result in a spectrum of superficially unrelated lesions that can cloud categorization (74, 66) .
Before there was deliberate genetic intervention, mouse models meant fortuitous natural mutations or exposure to specific chemicals via specific routes to induce cancers in virtually any rodent organ. Finding the genetic damage, natural or chemically induced, made careers and opened the fields of molecular biology. Genetically engineered mice (GEM) have been used to study roles of numerous genes and their proteins (28, 37, 46, 54, 94, 99) . Inactivation or modification of tumor suppressor genes has been relatively popular and successful. Because many human familial cancer syndromes have been reproduced fairly closely in mice by genetic engineering, it is the purpose of this review to compare and contrast the induced mouse models to their human counterparts. The models reviewed will include induced mutants (i.e., knockouts, knockins, and conditionals) but not transgenic mice.
CHARACTERISTICS OF HUMAN FAMILIAL
CANCER SYNDROMES The occurrence of various familial cancer syndromes has been reported for many years, but the specific genes responsible have only been found within the past 2 decades (Tables 1-6 ). Most cancer syndromes involve the loss of tumor suppressor gene control and/or loss of function mutations. Somatic mutations in these same genes are often found in sporadic cancer as well. The functions of these genes are many and often involve signaling pathways and growth regulatory networks. Heritable germline mutations, however, are only one important step in cancer susceptibility. Cancer development is a multistage process (25, 66, 94, 98) which may involve etiologic factors such as genetics and exogenous influences (diet, chemicals, irradiation). Molecular changes in specific genes have been found in all stages of cancer development from hyperplasias, dysplasias, intraepithelial neoplasias, and benign and malignant tumors in both humans and rodents (66, 94, 98) . Additional somatic mutations must occur in the various stages of carcinogenesis.
Germline mutations of important tumor suppressor genes do not confer susceptibility of all tissues in an affected 
Tsc2 Wrn Wt1 Vhl individual to cancer. Cancer always arises as an early preinvasive lesion, often focal hyperplasia or dysplasia. Thus, cancer susceptibility may involve the susceptibility to the early stages and multiplicity of that stage. Heritable genetic changes may increase susceptibility of other important genes to mutation during daily life exposures to exogenous and endogenous chemicals. Cancer syndromes are characterized by involvement of multiple organs, multiple tumors in the same organ and early mortality, often from ages 30-50. Interestingly, most examples of a human cancer syndrome are autosomal dominant and involve the heterozygous (+/−) state; heritabilty confers high risk of a cancer to any sibling that inherits a single allele. Loss of heterozygosity (LOH) is often found in tumors. The homozygous state (−/−) has never been found for most human cancer syndromes involving autosomal dominant traits. Mouse studies have highly suggested embryonic lethality as a possible reasons for this interesting finding but it may also be due to the rarity of two heterozygotes having children. It may be of value to study fertility rates and abortions in families with evidence of heritable mutations. We have used recent books (4, 74, 94) for reviewing the human heritable cancer syndromes as well as Multiple preneoplastic and precancerous lesions are found in organs developing tumors Genetic lesions/mutations are the same between affected individuals in the same families, but can differ between families; heterozygous state is the usual phenotype; loss of heterozygosity in tumors is common Genetic anomalies are the same between affected individuals; heterozygous state is common for tumorigenesis; loss of heterozygosity in tumors of +/− mice is common Inheritance may be simple (involving a single gene) or complex (involving multiple genes, or chromosomal defects).
Inheritance may be simple (involving a single gene) or complex (involving modifier genes as shown by mouse background strain effects). The homozygous null state may be embryo-lethal but has never been found
The homozygous null state is frequently embryo-lethal Relatively small number of subjects for study except for some syndromes Virtually limitless number of subjects for study Ethicolegal constraints regarding experimental study methods or therapies
No ethicolegal constraints in experimental study methods or therapies some published reviews (9, 10, 11, 28, 37, 46, 58, 68, 99, 102, 103) . The syndromes are summarized in Tables 1-6 . Online Mendelian Inheritance in Man, http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?db=OMIM , is a great resource for the human conditions as well.
MOUSE MODELS: OF MICE AND MEN As mentioned previously, hereditable cancers have been known to occur in animals other than humans far longer than they have been recognized in humans. The relatively short lifespans of most laboratory and conventional pet species, coupled to the greater emphasis on pedigree/records, make detection of unusual disease entities within related individuals fairly easy. Obtaining the same kinds of data from extended, 'outbred,' mobile human families is another story. Medical histories, if officially kept, are frequently held in disparate facilities and, until there was a need demonstrated, knowing such histories has not seemed especially important.
Mouse models are often similar to those found in human familial cancer syndromes. The human disease is usually much more complex and the mouse model a simplified version since it involves a more defined genetic background. Null mice (−/−) often die in utero (Table 7) , a finding not confirmed in humans with familial cancer syndromes. Embryonic lethality of null mice is often due to impaired gene functions in trophoblasts and vasculogenesis which do not allow the placenta to develop normally and support the embryo proper. In utero lethality suggests important functions for tumor suppressor genes in embryogenesis and other developmental processes.
A comparison of the characteristics of the naturally occurring human familial cancer syndromes and induced mouse models in general are shown in Table 8 .
Gastrointestinal Tumors
There are currently several mouse models of gastrointestinal neoplasia that mimic human colorectal cancer syndromes, both sporadic and familial (Table 1) . Several involve the murine homolog of the human APC gene either by direct mutation/deletion or by modulation by abnormal transcriptional and/or repair genes. The Min mouse line was derived 94 WARD AND DEVOR-HENNEMAN TOXICOLOGIC PATHOLOGY from a C57BL/6J male in which a germ-line mutation in mouse Apc was induced by ENU; it was the first to be widely used in the preliminary characterization of colon polyp formation and progression as well as the first to indicate the presence of modifying loci, a fact that helped to explain the spectrum of FAP and HNPCC (Table 1) . As genetic technology advanced, other models with targeted mutations in Apc-Apc 716 , Apc 1638N and Apc 1638T , Apc 580 -and in moderating genes, such as Smad4, Msh1 and -2, Mlh1, Ptgs, and PPARγ , have produced murine disease with similar phenotypes, transmission, and etiology as in human colorectal cancer (37, 46) . Availability of an animal model of a prevalent human neoplasia provides opportunities to study the biology of lesions and their response to various potential therapies at various time points in tumor development. However, a mouse is not a human and there are major differences in and difficulties with extrapolating information between species. In many of the genetically engineered mouse models of human colorectal cancer, adenomas and carcinomas are not limited to the colon, but occur throughout the GI tract. Lesions are proportionately smaller and colon lesions are fewer in number as compared to the thousands of polyps found in human FAP cases. Further differences include the fact that mouse models have a shorter lifespan; the homozygous state is frequently embryonic lethal; drug/supplement response may be very different; surgical interventions are often far more tedious; lesion morphologies may be significantly disparate. That being said, the Apc +/ 716 × Ptgs 2 double mutant has helped explain the suppressive effect of NSAIDS on colon polyp development by illustrating the interplay of COX-2 and prostaglandins (77, 83) . These mouse model studies have led to human clinical trials for NSAIDS compounds treating both familial polyposis (78, 91) and sporadic polyps.
Breast Cancer
One of the most active areas of investigation on a number of disciplinary fronts is breast cancer, and for good reason: The disease is currently the leading cause of death in American women between the ages of 40 and 55 and the incidence appears to be rising (94) . Although there is a significant subset of cancers considered to be familial, they account for a comparatively minor incidence of total cases diagnosed overall, and, since inheritance does not always follow typical Mendelian transmission, there remains the possibility of common environmental influences and/or interaction with other genetic factors.
Several genes have been isolated that appear to play major roles in the development of both familial and sporadic breast cancers. BRCA1 and BRCA2 have arguably received the most attention, particularly as concerns hereditary disease, but PTEN, TP53, and STK11/LKB1 are also under scrutiny. While epidemiological studies and clinical reports offer invaluable information, animal models provide the opportunity to study initiation, progression, and the mechanisms underlying the etiological spectrum. The mouse has been the major vehicle for such studies ( Table 2) ; targeted mutations in Pten and Stk11/Lkb have produced murine versions of Cowden disease (94) and Peutz-Jeghers Syndrome (58) , respectively, 2 disorders that predispose to the development of some rare human breast cancers with a mouse conditional mutant developing mammary tumors (1, 43, 52, 67, 70) . Multiple manipulations of Brca1 and Brca2 (frequently in conjunction with induced mutations in p53) in the mouse genome occasionally result in mammary tumors (16, 55, 56, 68) , but more often we see lymphomas and tumors produced in seemingly unrelated tissues (16, 68) . We have yet to produce a clear equivalent breast/mammary tumor model in terms of phenotype, and often the genetic acrobatics involved in producing any model, while based on potentially sound molecular biology, raise far more questions than provide answers.
So far, however, the best mammary mouse models remain to be transgenic mice and conventional strains with natural propensities for development of mammary carcinoma, even though the mouse mammary gland is not exactly a morphological and physiological human mammary gland.
Kidney Tumors
Several human familial kidney tumor syndromes have been found involving VHL, MET, BHD, TSC1, TSC2, WT1 and other genes (9, 102) . It has been difficult to replicate the human renal cancers. Null mice are often embryonic lethal (36, 45, 59, 96, 102) and true renal tumors have been found in only Tsc1 ( 48, 92) and Tsc2 (6, 75) heterozygous mice (Table 3) . Vascular tumors seen in human VHL are also seen in Vhl+/− and conditional null mice (34, 59) . These mouse models have not yet been used for developing methods of prevention and therapy.
Lymphoma and Leukemia
Human familial leukemias and lymphomas have been described with germline mutations in TP53, ATM, BLM, TN-FRS6/FAS, TNFRS6/FASL, FANCA and other related genes. Trp53 null and heterozygous mice are the most widely used GEM in biomedical research (21, 22, 28, 35, 47, 80, 100) into toxicology, chemoprevention and therapy (27, 39) . These mice develop thymic T-cell and B-cell marginal zone lymphomas and various sarcomas, but develop the mammary tumors seen in the human Li-Fraumeni Syndrome only when on a BALB/c mouse background (47) . Other mouse leukemia/lymphomas models that have been described for human familial diseases are listed in Table 4 .
Human familial autoimmune diseases are only reproduced in the mouse with the similar mutations in the same genes (Tn-fsf6/gld and Tnsff6/lpr), but these are natural mutants and not induced. We include them here for their comparative interest. Both the human and mouse conditions progress to lymphoma in older species (14, 94) .
Endocrine Tumors
Familial endocrine neoplasia syndromes involve MEN1 and MEN2 (74, 94) . We have added RB1 to this mix because Rb1 heterozygous mice develop multiple endocrine neoplasia syndromes ( Table 5 ). The Men1 and Rb1 null state is embryonic lethal in mice (12, 40, 51) . Rb1+/− mice do not develop retinoblastomas; these neoplasms are only seen in transgenic mice that have promoters targeting the retina. Instead, these mice develop multiple endocrine tumors in the thyroid, pituitary and adrenal glands (38, 40, 51, 60, 71, 72, 82, 85, 95, 100) . They have been used to study the effects of cooperating genes in tumor development (100) restriction (85) , and in gene therapy (82) . MEN1 is a human familial cancer syndrome which has been replicated in mouse heterozygotes and conditional nulls and heterozygotes (12, 13, 33) . Although parathyroid disease and tumors are prevalent in humans, islet cell tumors are the most prominent finding in mice. Men1 mutant mice are only recent productions and have yet not been used for drug development studies.
Neurological Tumors
Familial cancer syndromes characterized by tumors of the nervous system are associated with NF1 and NF2 and involve tumors of nerves and their cellular components (94, 103) . The Nf1 and Nf2 null state is embryonic lethal in mice (5, 65) and the Nf1 heterozygous adult mice do not develop these neural tumors; but other tumors are seen (5, 41, 50) ; (Table 5 ). Conditional Nf1 mutants do develop neurofibromas (104) . Nf2 heterozygous mice have osteosarcomas and other tumors (64) and conditional Nf2 mutants develop meningiomas if gene is inactivated in meningeal cells and schwannomas if inactivated in Schwann cells (29, 30, 44) .
Skin and Other Tumors
Benign and malignant skin tumors occur in families with germline mutations in XPA, PTCH and CDKN2 (Table 6 ). Mutant mice, however, do not develop skin tumors. Xpa null mice are very sensitive to carcinogens and ultraviolet carcinogenesis and have been used in short-term rodent carcinogenesis bioassays (3, (17) (18) (19) 69) . Ptch mutant mice do not develop skin tumors, but medulloblastomas and rhabdomyosarcomas are commonly found (32, 105) .
Mouse Repositories
Several repositories are now available for providing genetically engineered mice to investigators at reasonable cost http://emice.nci.nih.gov/emice/resources/repositories . They include the NCI Mouse Models of Cancer Consortium (MMHCC) web.ncifcrf.gov/researchresources/ mmhcc/default.asp , the Jackson Laboratory Induced Mutant Resource (IMR) www.jax.org/imr/notes.html , Taconic www.taconic.com , the NIH MMRRC www.mmrrc.org , the NIEHS CMGCC www.niehs.nih.gov/cmgcc/home. html and in Europe, EMMA www.emma.rm.cnr.it . Mice may also be available from individual investigators who have generated the GEM.
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